Skip to main content

Table 3 Main radiotherapy results of included studies

From: Charged particle therapy for high-grade gliomas in adults: a systematic review

Studies (year)

Median age (range)

Median dose in Gy (RBE)

Fraction (Fx)

Gy (RBE)/Fx

OS% (year)/median OS

PFS% (year)/ median PFS

Tsujii et al. [13]

AA:42.6

GBM:60.4

Proton alone (GBM):66.8 Gy; Photon + Protonboost (AA):86.8 Gy

Proton alone:23 to 25Fx

Photon:16 to 27FxProtonboost:15 to 17Fx

Proton alone:2.5 to 3.5 Gy

Photon + Protonboost:1.8 Gy

mOS(AA/GBM/AA + GBM):25,13,20mo

Fitzek et al. [15]

51(21–68)

Photon + Protonboost:total dose 93.5CGE(92.05 to 94.2 CGE)

Photon:1.8 Gy; Protonboost: 1.92 CGE

OS%:78%(1y), 34% (2y), 18%(3y); mOS 20mo

Mizoe et al. [27]

53(18–78)

Photon 50 Gy + CIRTboost:16.8 to 24.8GyE (16.8,18.4,20,22.4,24.8)

Photon:25Fx + CIRTboost:8Fx

Photon:2 Gy; CIRTboost:2.1 to 3.1 GyE

mOS: AA 35mo; GBM 17mo; mOS:GBM(high-dose, middle-dose, low-dose):26mo,19mo, 7mo

mPFS: GBM (high-dose, middle-dose, low-dose): 4mo, 7mo, 14mo

Mizumoto et al.[17]

56(31–76)

Photon 50.4 Gy; after 6 h protonboost 46.2GyE

Photon:28 Fx; after 6 h protonboost:28 Fx

Photon:1.8 Gy; after 6 h proton:1.65GyE

OS%:78%(1y),43%(2y); mOS 21mo

PFS%(1,2y):36%,13%

mPFS:9mo

Adeberg et al. [14]

Photon:57.9 (21.6–77.9); Photon + Proton boost:57.9 (20.0–77.0)

Photon:50.0(50.0 to 50.4) Gy/25(25 to 28) Fx; Photon + Protonboost:50 Gy + 10GyE/5Fx

Photon:25–28Fx; Protonboost:5Fx

Photon:1.8–2 Gy; Proton boost:2GyE

mOS: Photon:20.9mo;

Photon + protonboost:19.1mo

mPFS: Photon:7.2mo;

Photon + protonboost:8.8mo

Vora et al. [11]

56

Proton: 59.4 GyE (range 40–66 GyE)

15–33Fx

mOS 18.3 mo

OS%:39%(2y); mOS GBM 17mo

Kong et al. (25)

54.5(22–76)

Proton:60 GyE; Proton:50 GyE + CIRTboost:10 to12 GyE; Proton:60 GyE + CIRTboost: 9 to12GyE; Proton:34 GyE + CIRTboost:9 GyE

Proton:30Fx;

Proton:25Fx + CIRTboost 4 to 5Fx; Proton 30 Fx + CIRTboost 3Fx; Proton:10 Fx + CIRT boost:3Fx

Proton 2 GyE; Proton, 2 GyE + CIRTboost 2–3GyE; Proton 2 GyE + CIRTboost 3–4 GyE; Proton 3–4 GyE + CIRTboost 3 GyE

OS%(1y,1.5y):87.8%,72.8%;

OS%(1y,1.5y): AA 100%; GBM:77.4%, 61%

PFS%(1y,1.5y):74.2%,59.8%; PFS%(1y,1.5y): AA 100%; GBM:61.3%, 42.7%

Brown et al. [12]

GBM: IMRT:53 (26,82); PT:54.5 (33,72)

PTV1a:50 Gy

PTV2a:60 Gy

25Fx

2 Gy/2GyE

mOSa: IMRT 21.2mo

Proton 24.5mo

mPFSa: IMRT 8.9mo

Proton 6.6 mo

  1. OS overall survival; GBM glioblastoma; AA anaplastic astrocytoma; CGE Cobalt Gray Equivalent; mo month; y: year; RBE relative biological effectiveness; CIRT Carbon ion radiotherapy
  2. aPTV1 (Plan tumor volume1): CTV1 (Clinical tumor volume1) + 3–5 mm; PTV2:GTV (Gross tumor volume) + 3–5 mm; CTV include GTV + 2 cm anatomically constrained margin; Fx fractions
  3. aNo significant difference in mOS and mPFS (IMRT vs. Proton Therapy)